Lupin Launches Merzee® Capsules in the United States

Global pharma major Lupin Limited (Lupin) today announced that it has launched Merzee® (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules), 1 mg/20 mcg, in the US market, under exclusive license, marketing and distribution agreement with Slayback Pharma LLC (Slayback). Slayback had earlier launched this product in the US in February 2021.

Merzee® (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules), 1 mg/20 mcg is a generic equivalent of Taytulla® (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules), 1 mg/20 mcg of Allergan Pharmaceuticals International Limited.

Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules, 1 mg/20 mcg (RLD: Taytulla®) had estimated annual sales of USD 90 million in the U.S. (IQVIA MAT February 2022).

Shares of Lupin Limited was last trading in BSE at Rs. 784.60 as compared to the previous close of Rs. 772.95. The total number of shares traded during the day was 48647 in over 3001 trades.

The stock hit an intraday high of Rs. 786.85 and intraday low of 768.90. The net turnover during the day was Rs. 38036324.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Merzee USMarket SlaybackPharmaLLC